Prosperity Consulting Group LLC Invests $1.03 Million in United Therapeutics Co. (NASDAQ:UTHR)

Prosperity Consulting Group LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, HoldingsChannel.com reports. The fund bought 2,926 shares of the biotechnology company’s stock, valued at approximately $1,032,000.

Several other large investors have also recently made changes to their positions in the company. Parallel Advisors LLC boosted its position in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after acquiring an additional 30 shares during the last quarter. Signaturefd LLC grew its stake in shares of United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 30 shares during the period. Anchor Investment Management LLC increased its holdings in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after buying an additional 30 shares during the last quarter. Great Lakes Advisors LLC raised its position in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after buying an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its holdings in United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after acquiring an additional 33 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. cut their target price on United Therapeutics from $357.00 to $355.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Bank of America upgraded shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 17th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $390.17.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $353.64, for a total value of $3,536,400.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $911,330.28. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Raymond Dwek sold 3,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at approximately $499,747.50. This represents a 63.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 84,500 shares of company stock valued at $28,179,150. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Down 1.7 %

United Therapeutics stock opened at $291.38 on Friday. The company’s 50 day moving average is $308.67 and its two-hundred day moving average is $346.48. The firm has a market cap of $13.09 billion, a PE ratio of 12.80, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 52-week low of $233.31 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm posted $4.36 EPS. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.